

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

NCI-H2052

RRID:CVCL_1518

Type: Cell Line

Proper Citation

RRID:CVCL_1518

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1518

Proper Citation: RRID:CVCL_1518

Description: Cell line NCI-H2052 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pleural sarcomatoid mesothelioma

Defining Citation: [PMID:8806092](#), [PMID:10987304](#), [PMID:11030152](#), [PMID:11314036](#), [PMID:16630136](#), [PMID:17270034](#), [PMID:19853261](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20624269](#), [PMID:21245096](#), [PMID:21642991](#), [PMID:22460905](#), [PMID:23830731](#), [PMID:24926545](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25902174](#), [PMID:25984343](#), [PMID:26011428](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28553954](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2052

Synonyms: H2052, H-2052, H2052_MM, NCIH2052

Cross References: CLO:CLO_0008042, EFO:EFO_0002275, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5915, BioSample:SAMN03471041,

BioSample:SAMN03472597, BioSample:SAMN10987937, BioSamples:SAMEA100851, cancercellines:CVCL_1518, Cell_Model_Passport:SIDM00713, ChEMBL-Cells:ChEMBL3308119, ChEMBL-Targets:ChEMBL1075531, CLS:305836, Cosmic:688058, Cosmic:877272, Cosmic:877437, Cosmic:886390, Cosmic:980998, Cosmic:1032389, Cosmic:1146898, Cosmic:1481545, Cosmic:1522774, Cosmic:1541213, Cosmic:1571797, Cosmic:1749565, Cosmic:1891920, Cosmic:1963327, Cosmic:1995554, Cosmic:2474148, Cosmic:2758842, Cosmic:2759000, Cosmic:2759220, Cosmic-CLP:688058, DepMap:ACH-000153, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10847-111F1, GDSC:688058, GEO:GSM171854, GEO:GSM171855, GEO:GSM434305, GEO:GSM726264, GEO:GSM794345, GEO:GSM817098, GEO:GSM850299, GEO:GSM887398, GEO:GSM888476, GEO:GSM1670209, IARC_TP53:21553, IGRhCellID:H2052_MMGEO, IGRhCellID:NCIH2052, LiGeA:CCLE_326, PharmacoDB:NCIH2052_1059_2019, PRIDE:PXD030304, Progenetix:CVCL_1518, PubChem_Cell_line:CVCL_1518, Wikidata:Q54907907

ID: CVCL_1518

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260829T234731+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2052.

No alerts have been found for NCI-H2052.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. Molecular cell.

Hillen H, et al. (2024) A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models. Molecular cancer therapeutics, 23(1), 3.

Kulkarni A, et al. (2024) Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. EMBO reports, 25(9), 3944.

Hirai S, et al. (2024) Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. Molecular cancer therapeutics, 23(2), 212.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Monda JK, et al. (2023) HAPSTR1 localizes HUWE1 to the nucleus to limit stress signaling pathways. *Cell reports*, 42(5), 112496.

Maille E, et al. (2022) A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial. *International journal of cancer*, 150(11), 1889.

Furet P, et al. (2022) The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition. *ChemMedChem*, 17(19), e202200303.

Oehl K, et al. (2021) Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(8), 2277.

Abukar A, et al. (2021) Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A. *Cells*, 10(12).

Tan Y, et al. (2021) Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(4), 1200.

Yang H, et al. (2021) NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. *Cancers*, 13(7).

Duong BTV, et al. (2020) A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma. *EBioMedicine*, 61, 103031.

Yang H, et al. (2020) Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. *Cancers*, 12(8).

Xu D, et al. (2019) Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. *Cancers*, 11(10).